FLU VACCINE SAFETY NET PROGRAM Trademark
Trademark Overview
On Friday, September 7, 2001, a trademark application was filed for FLU VACCINE SAFETY NET PROGRAM with the United States Patent and Trademark Office. The USPTO has given the FLU VACCINE SAFETY NET PROGRAM trademark a serial number of 78083164. The federal status of this trademark filing is ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE as of Monday, July 29, 2002. This trademark is owned by Dubin Medical, Inc.. The FLU VACCINE SAFETY NET PROGRAM trademark is filed in the Computer & Software Services & Scientific Services category with the following description:
Healthcare and pharmaceutical safety management program
General Information
Serial Number | 78083164 |
Word Mark | FLU VACCINE SAFETY NET PROGRAM |
Filing Date | Friday, September 7, 2001 |
Status | 602 - ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE |
Status Date | Monday, July 29, 2002 |
Registration Number | 0000000 |
Registration Date | NOT AVAILABLE |
Mark Drawing | 1000 - Typeset: Word(s) / letter(s) / number(s) |
Published for Opposition Date | NOT AVAILABLE |
Trademark Statements
Goods and Services | Healthcare and pharmaceutical safety management program |
Classification Information
International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
US Class Codes | 100, 101 |
Class Status Code | 6 - Active |
Class Status Date | Monday, September 17, 2001 |
Primary Code | 042 |
First Use Anywhere Date | NOT AVAILABLE |
First Use In Commerce Date | NOT AVAILABLE |
Trademark Owner History
Party Name | Dubin Medical, Inc. |
Party Type | 10 - Original Applicant |
Legal Entity Type | 03 - Corporation |
Address | San Diego, CA 92110 |
Trademark Events
Event Date | Event Description |
Monday, July 29, 2002 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE |
Friday, November 23, 2001 | NON-FINAL ACTION MAILED |
Thursday, November 1, 2001 | ASSIGNED TO EXAMINER |